Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary.
Zaun G, Weber M, Metzenmacher M, Wiesweg M, Hilser T, Zaun Y, Liffers S, Pogorzelski M, Virchow I, Eberhardt W, Theurer S, Sabbah TA, Reissig TM, Stuschke M, Kürten C, Hussain T, Lang S, Kasper S, Fendler WP, Herrmann K, Schuler M. Zaun G, et al. Among authors: theurer s. J Nucl Med. 2023 Aug;64(8):1191-1194. doi: 10.2967/jnumed.122.265161. Epub 2023 Jun 15. J Nucl Med. 2023. PMID: 37321823
Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.
Welt A, Wiesweg M, Theurer S, Abenhardt W, Groschek M, Müller L, Schröder J, Tewes M, Chiabudini M, Potthoff K, Bankfalvi A, Marschner N, Schuler M, Breitenbücher F. Welt A, et al. Among authors: theurer s. Cancer Med. 2020 Jul;9(13):4527-4539. doi: 10.1002/cam4.3092. Epub 2020 Apr 30. Cancer Med. 2020. PMID: 32352244 Free PMC article. Clinical Trial.
Impact of 18F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients - A prospective evaluation of staging algorithms.
Kirchner J, Martin O, Umutlu L, Herrmann K, Bittner AK, Hoffmann O, Mohrmann S, Gauler T, Theurer S, Antke C, Esposito I, Kinner S, Schaarschmidt BM, Kowall B, Lütke-Brintrup D, Stang A, Becker AS, Antoch G, Buchbender C. Kirchner J, et al. Among authors: theurer s. Eur J Radiol. 2020 Jul;128:108975. doi: 10.1016/j.ejrad.2020.108975. Epub 2020 Apr 24. Eur J Radiol. 2020. PMID: 32371185 Free PMC article.
Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid 68Ga-DOTATOC PET/MRI.
Bruckmann NM, Rischpler C, Kirchner J, Umutlu L, Herrmann K, Ingenwerth M, Theurer S, Lahner H, Antoch G, Sawicki LM. Bruckmann NM, et al. Among authors: theurer s. Eur J Radiol. 2021 Apr;137:109588. doi: 10.1016/j.ejrad.2021.109588. Epub 2021 Feb 19. Eur J Radiol. 2021. PMID: 33639542
Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC.
Kersting D, Seifert R, Kessler L, Herrmann K, Theurer S, Brandenburg T, Dralle H, Weber F, Umutlu L, Führer-Sakel D, Görges R, Rischpler C, Weber M. Kersting D, et al. Among authors: theurer s. Cancers (Basel). 2021 Apr 6;13(7):1728. doi: 10.3390/cancers13071728. Cancers (Basel). 2021. PMID: 33917322 Free PMC article.
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
Weber M, Kersting D, Riemann B, Brandenburg T, Führer-Sakel D, Grünwald F, Kreissl MC, Dralle H, Weber F, Schmid KW, Herrmann K, Jentzen W, Grafe H, Rischpler C, Theurer S, Bockisch A, Nagarajah J, Fendler WP. Weber M, et al. Among authors: theurer s. Clin Cancer Res. 2022 Oct 3;28(19):4194-4202. doi: 10.1158/1078-0432.CCR-22-0437. Clin Cancer Res. 2022. PMID: 35594174 Free PMC article.
43 results